Oncolytics Biotech Inc.

ONCY

Healthcare|Biotechnology|US

$0.44

-0.01 (-2.09%)

DCF Value

$0.02

Cash / Share

$0.03

Next Earnings Report

Nov 11, 2026

EPS est. -$0.05

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Apr 8, 2026 (F-10POS). Possible dilution.

Upcoming Data Readouts (2)

Jul 2027

Est. completion

P1P2Anal Cancer Metastatic

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

NCT07280377n=122

Aug 2027

Est. completion

P2Ras-mutated Metastatic Colorectal Cancer

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322n=60

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2025

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

NCT04445844

Aug 2022

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

NCT04215146

Recent Press Releases

Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers

Nov 4, 2026 · GlobeNewsWire

Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers

Oct 27, 2026 · GlobeNewsWire

Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer

Oct 20, 2026 · GlobeNewsWire

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Oct 14, 2026 · GlobeNewsWire

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

Oct 12, 2026 · GlobeNewsWire

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Sep 29, 2026 · GlobeNewsWire

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Sep 28, 2026 · GlobeNewsWire

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

Sep 10, 2026 · GlobeNewsWire

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Aug 18, 2026 · GlobeNewsWire

SEC Filings (148)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 4, 2026	8-K	Material event	Document Index
Oct 27, 2026	8-K	Material event	Document Index
Oct 20, 2026	8-K	Material event	Document Index
Oct 14, 2026	8-K	Material event	Document Index
Oct 13, 2026	8-K	Material event	Document Index
Oct 6, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Oct 6, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Sep 29, 2026	8-K	Material event	Document Index
Sep 28, 2026	8-K	Material event	Document Index
Sep 10, 2026	8-K	Material event	Document Index
Aug 18, 2026	8-K	Material event	Document Index
Aug 12, 2026	10-Q	Quarterly report	Document Index
Jul 24, 2026	8-K	Material event	Document Index
Jul 20, 2026	8-K	Material event	Document Index
Jul 13, 2026	8-K	Material event	Document Index
Jul 8, 2026	8-K	Material event	Document Index
Jun 16, 2026	8-K	Material event	Document Index
Jun 2, 2026	8-K	Material event	Document Index
Jun 1, 2026	8-K	Material event	Document Index
May 22, 2026	8-K	Material event	Document Index
May 14, 2026	10-Q	Quarterly report	Document Index
May 4, 2026	8-K	Material event	Document Index
Apr 27, 2026	8-K	Material event	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	F-10POS	IPO / offering registration	Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index
Apr 8, 2026	AW		Document Index